Skip to main content

Table 1 Patient characteristics

From: Comparison of renal histopathology and gene expression profiles between severe COVID-19 and bacterial sepsis in critically ill patients

 

Control (n = 12)

Sepsis (n = 27)

COVID-19 (n = 6)

Age

59 (20–79)

67 (40–85)

65 (49–78)

Male:female

5:7

17:10

4:2

SAPS II score

n/a

68.8 (35–99)

 

BMI (kg/m2)

 

26.9 (20.8–49)

30.8 (26–37)

 Normal weight (BMI 18.5–24.9)

 

9

0

 Overweight (BMI 25–29.9)

 

14

3

 Obese (BMI > 30)

 

4

3

Days in ICU

n/a

3.6 (1–12)

30 (21–53)

Comorbidities

   

 Hypertension

3

8

1

 Diabetes Mellitus

1

3

2

 COPD or asthma

4

7

0

 Coronary disease

1

5

0

 Neurological

1

3

0

 Renal disease

0

0

0

 Vascular surgery

0

2

0

 Autoimmune disease

2

4

0

 Neoplasms (extra renal)

4

4

0

RIFLE stage

 Risk

n/a

0

n/a

 Injury

n/a

12

n/a

 Failure

n/a

15

n/a

 Loss of function

n/a

0

n/a

 End-stage renal disease

n/a

0

n/a

KDIGO AKI score

 0

n/a

n/a

1

 1

n/a

n/a

0

 2

n/a

n/a

0

 3

n/a

n/a

5

Need for RRT (Yes:no)

n/a

12:15

4:2

Mean biopsy time (mins)

n/a

33 (24–150)

21 (6–40)

Microorganisms

 Gram positive

n/a

12

3#

 Gram negative

n/a

23

1*

 Virus (norovirus & HIV)

n/a

2

0

 Fungi/yeast

n/a

5

0

 SARS-CoV-2

n/a

n/a

6

  1. ICU intensive care unit, SAPS II Simplified Acute Physiology Score II scoring system, BMI body mass index, RIFLE (risk, injury, failure, loss of kidney function, and end-stage kidney disease) classification, KDIGO AKI Kidney Disease Improving Global Outcomes acute kidney injury classification, RRT renal replacement therapy, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2. n/a not applicable. Microorganisms were detected in either the sputum, blood, urine or abdominal fluid
  2. *Multi-resistant pseudomonas in blood and sputum.
  3. #CVL or ECLS cannula-related infection with a coagulase-negative staphylococci